[{"abstract": "Pfizer, one of America\u2019s oldest drug makers, is again looking to renounce its corporate citizenship by buying a foreign rival.", "web_url": "https://www.nytimes.com/2015/10/30/business/dealbook/allergan-pfizer-deal.html", "snippet": "Pfizer, one of America\u2019s oldest drug makers, is again looking to renounce its corporate citizenship by buying a foreign rival.", "lead_paragraph": "Pfizer has long played an important role in United States history over its 166 years, including producing painkillers during the Civil War and penicillin in World War II.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web2/db-drug-web2-articleLarge.jpg", "height": 401, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/10/30/business/db-drug-web2/db-drug-web2-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 401}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web2/db-drug-web2-jumbo.jpg", "height": 684, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web2/db-drug-web2-superJumbo.jpg", "height": 1368, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web2/db-drug-web2-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/10/30/business/db-drug-web2/db-drug-web2-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web2/db-drug-web2-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Bid for Allergan Has Its Eyes on Ireland", "kicker": null, "content_kicker": null, "print_headline": "Pfizer Bid for Allergan Has Its Eyes on Ireland", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "persons", "value": "Picker, Leslie", "rank": 2, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 3, "major": "N"}, {"name": "persons", "value": "de la Merced, Michael J", "rank": 4, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 5, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 6, "major": "N"}], "pub_date": "2015-10-29T14:05:25+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Michael J. de la Merced and Leslie Picker", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Leslie", "middlename": null, "lastname": "Picker", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/140b7e0c-9df8-5f60-9f7c-bb8e752a476d", "word_count": 1090, "uri": "nyt://article/140b7e0c-9df8-5f60-9f7c-bb8e752a476d"}, {"abstract": "Allergan can hold out for a good price. But if Pfizer puts up a premium of more than 25 percent, it will risk paying away the benefits of a deal.", "web_url": "https://www.nytimes.com/2015/10/30/business/dealbook/pfizer-faces-challenges-in-pursuing-deal-for-a-lower-tax-rate.html", "snippet": "Allergan can hold out for a good price. But if Pfizer puts up a premium of more than 25 percent, it will risk paying away the benefits of a deal.", "lead_paragraph": "There\u2019s no easy cure for tax.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg", "height": 508, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 508}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-jumbo.jpg", "height": 867, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-superJumbo.jpg", "height": 1253, "width": 1480, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Faces Challenges in Pursuing Deal for a Lower Tax Rate", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": 5, "major": "N"}, {"name": "subject", "value": "Corporate Taxes", "rank": 6, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 7, "major": "N"}, {"name": "organizations", "value": "GlaxoSmithKline PLC", "rank": 8, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 9, "major": "N"}], "pub_date": "2015-10-29T16:43:38+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By John Foley", "person": [{"firstname": "John", "middlename": null, "lastname": "Foley", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4de024c5-722c-52a2-8e12-bdb90b4efdc4", "word_count": 401, "uri": "nyt://article/4de024c5-722c-52a2-8e12-bdb90b4efdc4"}, {"abstract": "Cheap capital, low interest rates and the challenges posed by the Affordable Care Act are driving health companies of all kinds, not just hospitals, to combine.", "web_url": "https://www.nytimes.com/2015/10/30/business/dealbook/health-care-companies-in-merger-frenzy.html", "snippet": "Cheap capital, low interest rates and the challenges posed by the Affordable Care Act are driving health companies of all kinds, not just hospitals, to combine.", "lead_paragraph": "In a fast-paced financial version of musical chairs, health care companies of all kinds \u2014 drug makers, hospital groups and insurers \u2014 have been frantically circling to be sure they are not left out of the latest frenzy of deal making. Mergers and acquisitions worth about $270 billion have been announced in the first nine months of 2015 in the United States, easily outpacing the activity in recent years, according to a tally by Mergermarket.", "print_section": "B", "print_page": "6", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg", "height": 508, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 508}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-jumbo.jpg", "height": 867, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-superJumbo.jpg", "height": 1253, "width": 1480, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Health Care Companies in Merger Frenzy", "kicker": null, "content_kicker": null, "print_headline": "Health Care Companies, Seeking Scale, Are Caught Up in a Merger Frenzy", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "persons", "value": "Abelson, Reed", "rank": 1, "major": "N"}, {"name": "subject", "value": "Health Insurance and Managed Care", "rank": 2, "major": "N"}, {"name": "subject", "value": "Patient Protection and Affordable Care Act (2010)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "subject", "value": "Hospitals", "rank": 5, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 6, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 7, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 8, "major": "N"}], "pub_date": "2015-10-29T20:25:03+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Reed Abelson", "person": [{"firstname": "Reed", "middlename": null, "lastname": "Abelson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/41d2a068-c7af-51e7-9203-2c8b0ce83a4d", "word_count": 1301, "uri": "nyt://article/41d2a068-c7af-51e7-9203-2c8b0ce83a4d"}]